Value added medicines: what value repurposed medicines might bring to society?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Policy barriers to drug repurposing in Europe: different stakeholder perspectives identified during survey-based shortlisting of key challenges.Health policy OPEN · 2026
   Article
2. Putative Antianxiety Property of Oral Enalapril Formulation in Mice: a Preclinical andCNS & neurological disorders drug targets · 2026
   Article
3. H1 Antihistamines-Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment.Cancers · 2024
   Review
4. In silico exploration of anti-prostate cancer compounds from differential expressed genes.BMC urology · 2024
   Article
5. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.British journal of cancer · 2024
   Review
6. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-airClinical and translational allergy · 2023
   Article
7. How to balance valuable innovation with affordable access to medicines in Belgium?Frontiers in pharmacology · 2022
   Article
8. Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings.Cost effectiveness and resource allocation : C/E · 2021
   Article
9. Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.Cost effectiveness and resource allocation : C/E · 2021
   Review
10. Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy.Frontiers in medical technology · 2021
    Review
11. The Mixed-Method 5W2D Approach for Health System Stakeholders Analysis in Quality of Care: An Application to the Moroccan Context.International journal of environmental research and public health · 2019
    Article
12. On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients.Frontiers in pharmacology · 2019
    Article
13. The Added Value of Liquid Antipsychotics: The Case of Quetiapine.Current clinical pharmacology · 2019
    Review
14. Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer.Health economics review · 2018
    Article
15. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.mAbs
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as